Trade Names:Akineton- Tablets 2 mg (as hydrochloride)- Injection 5 mg/mL (as lactate)
Biperiden is a weak peripheral anticholinergic agent and possesses nicotinolytic activity.
29% bioavailable; C max is 4 to 5 mcg/L; T max is 1 to 1.5 h.
The t ½ is 18.4 to 24.3 h.
Treatment of all forms of parkinsonism; control of extrapyramidal disorders secondary to neuroleptic drug therapy.
Narrow angle glaucoma; bowel obstruction; megacolon.
PO 2 mg 3 times daily to 4 times daily to max 16 mg/day. Dosage must be individualized.Drug-Induced Extrapyramidal DisordersAdults
PO 2 mg every day to 3 times daily. IM/IV 2 mg repeated every 30 min until symptoms resolve, but not more than 4 consecutive doses (or 8 mg) per day.
May increase anticholinergic adverse reactions.Digoxin
May increase digoxin serum levels, especially with slow-dissolution oral digoxin tablets.Haloperidol
May worsen schizophrenic symptoms; may decrease haloperidol serum levels; tardive dyskinesia may develop. May decrease action of phenothiazines. May increase incidence of anticholinergic adverse reactions.
None well documented.
Mild transient orthostatic hypotension; bradycardia; tachycardia.
Blurred vision; narrow-angle glaucoma; pupillary dilation.
Drowsiness; euphoria; disorientation; agitation; memory loss; disturbed behavior.
Dry mouth; constipation; GI irritation.
Hyperthermia; heat stroke.
Category C .
Safety and efficacy not established.
Patients over 60 yr of age may have increased adverse reactions; dosage reduction and observation may be needed.
Use with caution in patients with glaucoma, prostatic hypertrophy, epilepsy, cardiac arrhythmias, hypertension, hypotension, tendency toward urinary retention, liver or kidney disorders, obstructive disease of GI or GU tract, tachycardia or those who are taking other drugs with anticholinergic activity.
Fatal hyperthermia has occurred. Use with caution during hot weather.
Narrow-angle glaucoma may occur.
Characterized by adverse reactions. Also: Circulatory collapse, cardiac arrest, respiratory depression or arrest, CNS depression preceded or followed by stimulation, intensification of mental symptoms or toxic psychosis in mentally ill patients treated with neuroleptic drugs (eg, phenothiazines), shock, coma, stupor, seizures, convulsions, ataxia, anxiety, incoherence, hyperactivity, combativeness, anhidrosis, hyperpyrexia, fever, hot/dry/flushed skin, dry mucous membranes, dysphagia, foul-smelling breath, decreased bowel sounds, dilated and sluggish pupils.